News

In patients with active cancer, the risk of venous thromboembolism (VTE) is four to seven times higher than in people of the same age without cancer, while chemotherapy

Under the multi-year program, the company will award a total of about $3m in grants to investigators in the US. This program is an extension of the company’s

Varlilumab is the company’s fully human monoclonal agonist antibody that binds and activates CD27, a critical co-stimulatory molecule in the immune activation cascade. The Phase I portion of

Synjardy is a combination of empagliflozin, a sodium glucose cotransporter 2 (SGLT2) inhibitor, and metformin hydrochloride (HCl), commonly prescribed to treat T2D. In the EU, empagliflozin was approved

Mircera is used to treat symptomatic anaemia associated with chronic kidney disease (CKD) in adult patients. The company said that the drug represents a complement to its existing

Zafatek (trelagliptin succinate) controls blood glucose levels by selectively and continually inhibiting DPP-4, an enzyme that causes the inactivation of glucagon-like peptide-1 and glucagon-dependent insulinotropic polypeptide, incretin hormones

The new European patent comprises composition of matter claims directed to novel formulations for topical application to the nails. The corresponding U.S. patent was also granted earlier this

MCL-1 is one of the top-ten most amplified genes in all of human cancer and is vital to tumor development and cancer progression. In collaboration with the Broad

The current work builds upon the Company’s Cancer Immunotherapy Platform. This patent application covers intellectual property that provides a means of specifically inducing dendritic cells to internally generate